Physical Activity in Persons With Parkinson's Disease (ActivPARK)
13. Mai 2026 aktualisiert von: Erika Franzén, Karolinska Institutet
Physical Activity in Persons With Parkinson's Disease - a Longitudinal Cohort Study
This project aims to identify why some people with Parkinson's disease (PwPD) become less physically active, and which factors support or hinder activity. Understanding these factors is essential for developing person centred interventions and effective support that can be implemented in routine healthcare. A national, multicentre longitudinal cohort study will be conducted including approx 450 PwPD from five Swedish regions (including the internal pilot NCT06901869). Physical activity will be measured objectively with activity monitors, combined with clinical assessments and digital questionnaires over four years. The primary outcome is physical activity level (accelerometer measured decline), and exposure variables include physical, cognitive, disease specific, social, environmental, motivational, and personal factors. Data collection involves clinical tests, questionnaires, accelerometer data, and patient reported experiences.
This is a continuation of an internal pilot study NCT06901869. The study will enable early identification of those at risk for declining activity and guide development of person centred, evidence based interventions. Long term, it aims to integrate activity monitoring and risk factor screening into routine care to improve health and quality of life for PwPD.
Studienübersicht
Status
Rekrutierung
Studientyp
Beobachtungs
Einschreibung (Geschätzt)
450
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienkontakt
- Name: Compliance Office Karolinska Insitutet
- Telefonnummer: +46852480000
- E-Mail: compliance@ki.se
Studieren Sie die Kontaktsicherung
- Name: Erika Franzén
- Telefonnummer: +46852488878
- E-Mail: erika.franzen@ki.se
Studienorte
-
-
-
Stockholm, Schweden
- Rekrutierung
- Karolinska University Hospital
-
Kontakt:
- Erika Franzén, PhD
- Telefonnummer: +46852488878
- E-Mail: erika.franzen@ki.se
-
Kontakt:
- LIsa Sandberg, MSc
- E-Mail: lisa.sandberg@ki.se
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Nein
Probenahmeverfahren
Nicht-Wahrscheinlichkeitsprobe
Studienpopulation
People with Parkinson's disease with mild to severe severity (Hoehn & Yahr 1-4) of all ages
Beschreibung
Inclusion Criteria:
- People diagnosed with idiopathic Parkinson's disease
- Hoehn & Yahr 1 to 4
Exclusion Criteria:
- Hoehn & Yahr 5 (i.e. wheelchair bound or bedridden unless aided)
- Unable to perform critical physical activity and clinical assessments
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
|---|
|
People with Parkinson´'s disease
No intervention
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Physical activity - low and moderate intensity
Zeitfenster: Baseline and yearly follow-ups for 3 years
|
The primary outcome is changes over time in PA (i.e.
low + moderate-vigorous intensity PA in time spent per day) measured with accelerometers (Actigraph GT3X+, Pensacola, FL, US) during 7 days in people with Parkinson's disease everyday life.
|
Baseline and yearly follow-ups for 3 years
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Physical activity - total vector magnitude
Zeitfenster: Baseline and yearly follow-ups for 3 years
|
The secondary outcomes are change over time in total vector magnitude measured with accelerometers (Actigraph GT3X+, Pensacola, FL, US) during 7 days in people with Parkinson's disease everyday life.
|
Baseline and yearly follow-ups for 3 years
|
|
Physical activity - low intensity
Zeitfenster: Baseline and yearly follow-ups for 3 years
|
The secondary outcomes are change in time spent in low intensity physical activity per day measured with accelerometers (Actigraph GT3X+, Pensacola, FL, US) during 7 days in people with Parkinson's disease everyday life.
|
Baseline and yearly follow-ups for 3 years
|
|
Physical activity - moderate high intensity
Zeitfenster: Baseline and yearly follow-ups for 3 years
|
The secondary outcomes are change in time spent in moderate-vigorous physical activity per day measured with accelerometers (Actigraph GT3X+, Pensacola, FL, US) during 7 days in people with Parkinson's disease everyday life.
|
Baseline and yearly follow-ups for 3 years
|
|
Physical activity- sedentary
Zeitfenster: Baseline and yearly follow-ups for 3 years
|
The secondary outcomes are change in sedentary time per day measured with accelerometers (Actigraph GT3X+, Pensacola, FL, US) during 7 days in people with Parkinson's disease everyday life.
|
Baseline and yearly follow-ups for 3 years
|
|
Physical activity - steps
Zeitfenster: Baseline and yearly follow-ups for 3 years
|
The secondary outcomes are change in steps per day measured with accelerometers (Actigraph GT3X+, Pensacola, FL, US) during 7 days in people with Parkinson's disease everyday life.
|
Baseline and yearly follow-ups for 3 years
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Kognitive Leistung
Zeitfenster: Grundlinie und 3-Jahres-Follow-up
|
Bewertet mit der Montreal Cognitive Assessment (MOCA), 0-25, höherer Punktzahl = besser
|
Grundlinie und 3-Jahres-Follow-up
|
|
Disease severity, Parkinsons symptoms
Zeitfenster: Baseline and 3 year follow-up
|
Disease severity measured with the Movement Disorders Society -Unified Parkinson's Disease Rating Scale) parts 1 to 4. Higher scores = worse/more symptoms |
Baseline and 3 year follow-up
|
|
Gait
Zeitfenster: Baseline and 3 year follow-up
|
Gait speed in m/s measured with the 10 meter walking test or through gait analysis.
|
Baseline and 3 year follow-up
|
|
Balance performance
Zeitfenster: Baseline and 3 year follow-up
|
Assessed with the Mini-BESTest.
Mini-Balance Evaluation Systems Test a rating scale for dynamic balance incorporating 14 different balance and gait items that were assessed by a physical therapist on a scale from 0-2. 0-28 points with higher scores indicating better balance control
|
Baseline and 3 year follow-up
|
|
Anxiety and depression
Zeitfenster: Baseline and yearly follow-ups for 3 years
|
Assessed with Hospital Anxiety and Depression Scale (HADS), 0-24 on the depression and anxiety part respectively.
Lower score=better
|
Baseline and yearly follow-ups for 3 years
|
|
Motivation
Zeitfenster: Baseline and yearly follow-ups for 3 years
|
Assessed with the Behavioural Regulation in Exercise Questionnaire (BREQ 4), a 28-item survey that measures exercise motivation.
The questionnaire uses a 7-point Likert scale, ranging from one to seven.
Maximum 196.
Higher scores = higher motivation
|
Baseline and yearly follow-ups for 3 years
|
|
Self-efficacy
Zeitfenster: Baseline and yearly follow-ups for 3 years
|
Assessed with the Self-efficacy and motivation for exercise/physical activity (ESES).
10 questions rated on a 4 point Likert scale.
Maximun 40 points, higher scores= better self-efficacy
|
Baseline and yearly follow-ups for 3 years
|
|
Physical activity history and preferences,
Zeitfenster: Baseline
|
Self-made questions on physical activity history and preferences
|
Baseline
|
|
Self assessed cognitive function
Zeitfenster: Baseline and yearly follow-ups for 3 years
|
Assessed with Executive function questionnaire (DEX), 20 items scored 1 to 4, max 80, more scores= worse
|
Baseline and yearly follow-ups for 3 years
|
|
Non-Motor Symptoms
Zeitfenster: Baseline and yearly follow-ups for 3 years
|
Non-Motor Symptoms Questionnaire (NMSQ), 30 questions with yes/no answer.
More yes answers = more non-motor symptoms
|
Baseline and yearly follow-ups for 3 years
|
|
Walking ability- self rated
Zeitfenster: Baseline and yearly follow-ups for 3 years
|
WALK-12G questionnaire, 0 and 42 points, with higher scores reflecting greater perceived walking difficulties (higher=worse)
|
Baseline and yearly follow-ups for 3 years
|
|
Freezing of gait - self-assessed
Zeitfenster: Baseline and 3 year follow-up
|
Freezing of gait questionnaire (FOGQsa), 6 questions/items, scored 1 to 5 (higher=worse)
|
Baseline and 3 year follow-up
|
|
Balance confidence
Zeitfenster: Baseline and yearly follow-ups for 3 years
|
Activities specific balance confidence (ABC scale), 16 items which is scored 1 to 10 and then divided by 16. 0-100%, higher % = better
|
Baseline and yearly follow-ups for 3 years
|
|
Fatigue
Zeitfenster: Baseline and yearly follow-ups for 3 years
|
Parkinson's Fatigue Scale (PFS-16), 16 items scored 1 to 5 from strongly disagree to strongly agree .
more points/score= worse.
|
Baseline and yearly follow-ups for 3 years
|
|
Disability
Zeitfenster: Baseline and 3 year follow-up
|
World health organization (WHO) disability assessment schedule (Whodas 2.0), 12 self-assessed questions (12 to 60) more points=worse
|
Baseline and 3 year follow-up
|
|
Sleep
Zeitfenster: Baseline and 3 year follow-up
|
Scales for Outcomes in Parkinson's disease - Sleep (SCOPA-SLEEP), 4 parts, A-2 questions, B-5 questions , C-1 question and D- 6 questions.
Higher= worse
|
Baseline and 3 year follow-up
|
|
Self-rated pain
Zeitfenster: Baseline and yearly follow-ups for 3 years
|
Assessed with visual analog scale, VAS from 0 to 100
|
Baseline and yearly follow-ups for 3 years
|
|
Health related quality of life
Zeitfenster: Baseline and yearly follow-ups for 3 years
|
Parkinson's Disease Questionnaire (PDQ39).
The Parkinson's Disease Questionnaire (PDQ-39) assesses how often people with Parkinson's experience difficulties across 8 dimensions of daily living (mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communications and bodily discomfort).
The sum score is as a percentage score ranging between 0 and 100.
Higher is better
|
Baseline and yearly follow-ups for 3 years
|
|
Wellbeing
Zeitfenster: Baseline and yearly follow-ups for 3 years
|
The WHO- Five Well-Being Index (WHO-5), 5 questions ranging from 0 to 5, 0-25, higher=better
|
Baseline and yearly follow-ups for 3 years
|
|
Nutrition
Zeitfenster: Baseline and 3 year follow-up
|
Mini Nutritional Assessment, max 14. higher = better
|
Baseline and 3 year follow-up
|
|
Socioeconomic status
Zeitfenster: Baseline
|
Education and income level.
|
Baseline
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Erika Franzén, Karolinska Institutet
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Tatsächlich)
15. Januar 2026
Primärer Abschluss (Geschätzt)
31. Dezember 2030
Studienabschluss (Geschätzt)
30. Januar 2031
Studienanmeldedaten
Zuerst eingereicht
7. Mai 2026
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
7. Mai 2026
Zuerst gepostet (Tatsächlich)
13. Mai 2026
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
15. Mai 2026
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
13. Mai 2026
Zuletzt verifiziert
1. Mai 2026
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 4-438/2024
- 2024-07526-01 (Andere Kennung: Swedish Ethical Review Authority)
- 06901869 (Andere Kennung: Clinical Trials registration -pilot study)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
JA
Beschreibung des IPD-Plans
The datasets generated during and/or analysed during the current study are not publicly available due to Swedish and EU personal data legislation but are available from the principal investigator on reasonable request.
Any sharing of data will be regulated via a data transfer and user agreement with the recipient, provided that the recipient has an approved ethics application.
IPD-Sharing-Zeitrahmen
We plan to share this when applicable on OSF or similar
IPD-Sharing-Zugriffskriterien
The datasets generated during and/or analysed during the current study are not publicly available due to Swedish and EU personal data legislation but are available from the principal investigator on reasonable request.
Any sharing of data will be regulated via a data transfer and user agreement with the recipient.
Art der unterstützenden IPD-Freigabeinformationen
- SAFT
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Nein
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Nein
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Physische Aktivität
-
Affiliated Hospital to Academy of Military Medical...Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Peking University...RekrutierungAltersspanne ≥16 Jahre, Geschlecht unbegrenzt | Histopathologie bestätigtes diffuses großzelliges B-Zell-Lymphom oder hochgradiges B-Zell-Lymphom | Erhaltene vorherige Erstlinien-Chemotherapie für DLBCL oder HGBL, CR für vier Zyklen nicht erreicht oder rezidiviert | Mindestens eine... und andere BedingungenChina